Best of ASCO - 2014 Annual Meeting

 

Welcome

Outcomes

Health Services Research, Clinical Informatics, and Quality of Care

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A nationwide analysis of hospitalized patients with malignancy-related Sweet syndrome (MRSS).

Yuzhou Liu

e18742

A novel approach to mine the Veterans Administration Informatics and Computing Infrastructure (VINCI) allows one to assess the efficacy of cancer therapies: Abiraterone and enzalutamide in Veterans with metastatic prostate cancer (PC).

Harshraj Leuva

6586

ADVERSE EVENTS WITH G-CSF FOR NEUTROPENIA IN CANCER.

Debra E. Irwin

e18762

An updated analysis of new oncologic drug approvals at FDA by expedited program.

Dianne Pulte

e18747

Assessing the difference in efficacy and effectiveness of cancer systemic treatment (tx): A comparison of clinical trial (CT) overall survival (OS) and toxicity data with population-based, real world (RW) OS data.

Cameron Phillips

6581

Association of diabetes with colorectal cancer treatment and outcomes.

Arjun Iyengar

e18752

Beyond BRCA1/2: Clinician-reported utility 3 years post panel testing.

Edward D. Esplin

e18705

Biases in assessment and reporting of health-related quality of life (QoL): A systematic review of oncology randomized phase III trials published between 2012 and 2016.

Laura Marandino

e18719

Clinical outcome and prognostic factors for Asian patients treated in a phase I study at the National University Cancer Institute, Singapore (NCIS).

Vaishnavi Muthu

e18748

Compliance with guideline-based empiric antimicrobial therapy for febrile neutropenia in adult Filipino patients and their effect on outcomes.

Frederic Ivan Leong Ting

e18757

Current burden of chemotherapy induced anemia and patterns of erythropoiesis-stimulating agents utilization.

Wing Yu Tang

e18765

Defining non-inferiority margins for quality of surgical resection for rectal cancer.

Sergio A Acuna

e18760

ECOG score analysis as a proxy for health-related quality of life assessment in patients with poor or intermediate risk metastatic renal cell carcinoma from the CABOSUN trial (Alliance A031203).

Darren R. Feldman

e18690

Effect of blinding on completion rate of patient-reported outcome measures in FDA cancer trial submissions, 2007-2017.

Jessica Roydhouse

6572

Effect of race on completion of chemotherapy in early stage breast cancer: A systematic review and meta-analysis.

Angela K Green

e18749

Engagement in cardiovascular disease preventive and cardiac outcomes in colon cancer survivors.

Sally C Lau

e18700

Enrollment in high-deductible health plans and access to care, out-of-pocket spending, and hospital emergency department use among cancer survivors.

Zhiyuan Zheng

6582

Evaluating disparities in clinical trial accrual in an urban academic radiation oncology department.

Alyssa M Asaro

e18759

Evolving epidemiology of lung cancer in California: 1990-2014.

Kevin Pan

e18724

Expanding enrollment of underrepresented populations on early phase clinical trials: An analysis of participation among adolescent and young adults (AYA) with advanced cancers on phase I clinical trials.

Ishwaria Mohan Subbiah

e18714

Exploring open-label bias in patient-reported outcome (PRO) emotional domain scores in cancer trials.

Paula Banerjee Chakravarti

e18702

Factors associated with quitting action following smoking cessation counseling.

Kadir Mutlu Hayran

e18750

Factors predicting molecular testing and its impact on survival in racially diverse patients with advanced, non-small cell lung cancer: A retrospective, population-based analysis using administrative claims data.

Jennifer L. Ersek

e18691

FDA acceptance of surrogate endpoints in later lines of therapy.

Emerson Yu-sheng Chen

6517

Feasibility trial of collecting patient-generated health data using a wearable device and electronic patient-reported outcomes in cancer patients.

Tempei Miyaji

e18725

Frequency of post-treatment surveillance and survival in localized prostate cancer: AFT-30 a national study.

Ronald C. Chen

6503

Hematopoietic stem cell transplant (HSCT) utilization in Hodgkin lymphoma (HL) after treatment failure from a statewide claims database.

Anem Waheed

e18739

Hepatitis c virus infection risk tool for patients with cancer.

Jessica Hwang

e18694

Hospital utilization and disposition among patients with malignant bowel obstruction: A population-based comparison of surgical to medical management.

Sarah Bateni

6571

Identifying chemotherapy-induced peripheral neuropathy (CIPN) and its treatment using claims data: A URCC NCORP and NIH Collaboratory study.

Jennifer S. Gewandter

e18707

Impact of clostridium difficile infection on mortality among gastrointestinal (GI) and lung cancers.

Stuthi Perimbeti

e18735

Impact of clostridium difficile infection on short-term outcomes in hospitalized patients with hematologic malignancies: A national sample.

Kahee A. Mohammed

e18711

Impact of denosumab on skeletal-related events in solid tumors.

Sridevi Rajeeve

e18754

Impact of iron deficiency in patients with hepatocellular carcinoma: Data from the nationwide inpatient sample from 1999-2014.

Erika Correa

e18751

Impact of liquid-biopsy in the therapeutic decision making process in a Peruvian institution.

Luis Schwarz

e18761

Impact of pre-existing cardiovascular disease (CVD) on patterns of care and outcomes in breast cancer (BC).

Winson Y. Cheung

e18723

Incidence of hypersensitivity reactions to carboplatin or paclitaxel in patients with ovarian, Fallopian tube, or primary peritoneal cancer with or without BRCA1 or BRCA2 mutations.

Andrew Garcia

e18758

Investigating hospice utilization for oncology patients using a claims database.

Margaret C. Horvath

6570

Liver metastasis as an independent predictor for mortality in patients who developed tumor lysis syndrome: Analysis of 132 patients with solid tumors.

Jonathan Harmon

e18766

Longitudinal precision oncology experience in solid tumors at the Cleveland Clinic.

Meena Sadaps

e18710

Long-term survival and performance status of cancer patients after discharge from ICU (intensive care unit).

Marta Zafra

e18744

Mobidity and mortality related to therapy in cirrhotic breast cancer patients.

Yu Liu

e18740

Objective metrics of patient activity: Use of wearable trackers and patient reported outcomes in predicting unexpected healthcare events in cancer patients undergoing highly emetogenic chemotherapy.

Alexander S. Martin

6519

Off-label use of everolimus and associated factors in non-elderly cancer patients with private insurance in the United States.

Yan Xing

e18718

Optimizing brief, focused symptom assessment in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): The FHNSI-10.

Sara Shaunfield

e18743

Outcome of patients with solid tumors admitted to intensive care units.

Melissa Phillips

e18701

Outcomes in non-Hodgkin lymphoma by Latino country-of-origin (COO).

Oscar Calzada

e18727

Patterns of patient-reported chemotherapy toxicities across twenty-eight ambulatory oncology settings.

Christopher Ryan Friese

e18721

Population based analysis of male patients with breast cancer.

Osama Ahmed

e18715

Post-marketing modifications of drug labels for cancer drugs approved by the US Food and Drug Administration between 2006 and 2016 with and without supporting randomized controlled trials.

Daniel Shepshelovich

e18717

Predicting acute care use following initiation of systemic therapy for solid tumors.

Robert C Grant

6576

Prediction of venous thromboembolism (VTE) in multiple myeloma (MM): Myeloma clot score (MCS).

Kristen Marie Sanfilippo

6585

Predictive ability of the khorana score for venous thromboembolism (VTE) in multiple myeloma (MM).

Kristen Marie Sanfilippo

e18733

Predictors of erlotinib utilization and the impact of erlotinib use on overall survival in advanced, non-small cell lung cancer.

Jennifer L. Ersek

e18741

Prevalence and short-term outcomes of venous thromboembolism in hospitalized patients with hematologic malignancies: A nationwide analysis.

Kahee A. Mohammed

e18728

Prevalence of quality of life(QoL) outcomes and association with survival in cancer clinical trials.

Bishal Gyawali

6573

PRO labeling for oncology drugs approved by FDA and EMA, 2012-2016.

Ari Gnanasakthy

e18730

Prognostic factors in critically ill patients with solid cancer admitted to medical intensive care unit.

Camille Baylot

e18745

Prospective linkage of clinical trial and administrative databases: Acceptability to patients and research ethics boards.

Annette E. Hay

e18692

Racial, age, and sex disparities in chronic lymphocytic leukemia (CLL) patients treated with novel therapies.

Meghan Thompson

6577

Real world data in colorectal cancer: A retrospective analysis of overall survival in metastatic colorectal cancer patients between 2011-2015 treated in Spain—Preliminary results (RWD-ACROSS study).

Carles Pericay

e18731

Real-world characteristics, treatment patterns and outcomes of RET+ NSCLC compared to other rare driver mutations.

William Bruce Wong

e18706

Real-world data (RWD) on tumor response (rwTR) in advanced non-small cell lung cancer (aNSCLC) patients receiving cancer immunotherapy and targeted therapies.

Michael Lu

6578

Relationship of self-reported food insecurity and symptom burden in patients with cancer.

Emmaline Reed Longnecker

e18771

Reporting of research biopsies in clinical trials in oncology: Analysis of clinicaltrials.gov.

Christine Megerdichian Parseghian

e18720

Retrospective analysis of complications following central venous port insertions: A single institution experience.

William Paul Skelton

e18767

Safety and efficacy of direct oral anticoagulants in the treatment of venous thromboembolism in cancer patients: A meta-analysis of randomized controlled trials.

Muhammad Husnain

e18699

State breast density inform mandate laws and utilization of adjunctive screening tests and cancer detection following screening mammography.

Cary Philip Gross

6579

Successful automated normalization of cancer outcomes for half a million patients across four disparate health systems.

Paul D. Tittel

e18763

Survival and glycemic control in patients with colorectal cancer and diabetes mellitus.

Nina J. Karlin

e18755

Survival of patients with advanced solid tumors who receive treatment in community based oncology group practices is comparable to randomized controlled trials (RCT).

Rudolf Weide

e18770

The impact of concomitant use of tyrosine kinase inhibitors and proton pump inhibitors on survival in older adults with cancer.

Manvi Sharma

e18732

The impact of palliative care consultation on overall survival and aggressive care at the end-of-life in unresectable pancreatic cancer.

Caitlin Lees

e18729

The prognostic significance of combined gleason scores and PSA values as indicators of age standardized relative five-year survival: An analysis of the SEER database 2004-2014.

Erika Correa

e18753

The prognostic significance of PSA as an indicator of age standardized relative survival: An analysis of the SEER database 2004-2014.

Mariola A. Vazquez Martinez

e18768

Total parenteral nutrition utilization in metastatic cancer patients: A nationwide 10-year analysis from 2006 to 2015.

Yuzhou Liu

e18693

Toward understanding toxicity over time (ToxT) in myeloma cooperative group trials: Feasibility of a novel longitudinal adverse event analysis in ECOG-ACRIN E1A06.

Susanna J. Jacobus

6580

Treatment patterns and costs in cutaneous squamous cell carcinoma (CSCC) patients with nodal dissection, chemotherapy, and/or radiation therapy.

Emily S Ruiz

e18703

Treatment patterns of tenosynovial giant cell tumor among commercially insured patients: A retrospective claims analysis.

Feng Lin

e18737

Trend of second primary malignancy in Hodgkin lymphoma.

Mahesh Nepal

e18713

Trends in chronic opioid therapy among cancer survivors.

Talya Salz

6584

Use of supportive care and risk of febrile neutropenia (FN) among patients receiving myelosuppressive chemotherapy for solid tumors or non-Hodgkin's lymphoma (NHL) at four US health systems.

Derek Weycker

e18756

Using administrative laboratory result data to describe adverse events.

Tamara P. Miller

e18698

Validity of using cancer registry data for comparative effectiveness research.

Zachary David Guss

6574

Work status after treatment for breast cancer: A controlled, prospective, longitudinal study of an ethnically diverse cohort.

Victoria Susana Blinder

6583